Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Mol Cancer
; 22(1): 200, 2023 12 09.
Article
en En
| MEDLINE
| ID: mdl-38066564
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Receptores de Antígenos de Linfocitos T
/
Receptores Quiméricos de Antígenos
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article